To further validate the clinical utility of the model, we constructed a decision curve analysis (DCA) to compare the prognostic performance of the MRPL family model with that of other established tumor biomarkers, including AFP, MKI67, and KRT19. The gene discussed is KRT19; the disease is neoplasm.